ebola
viru
epidem
began
west
africa
affect
individu
unlik
earlier
ebola
outbreak
larg
confin
isol
villag
one
struck
popul
citi
sustain
persontoperson
transmiss
end
epidem
remain
uncontrol
current
drug
treat
ebola
urgenc
emerg
trigger
epidem
two
type
abbas
therapi
use
convalesc
sera
patient
recov
mab
cocktail
known
zmapp
produc
plant
although
time
write
news
releas
efficaci
abbas
therapi
larg
favor
evid
anecdot
firm
conclus
made
formal
clinic
trial
done
encourag
world
health
organ
therefor
refrain
comment
efficaci
ab
therapi
ebola
viru
focu
instead
concurr
epidem
bring
focu
promis
therapi
also
highlight
difficulti
involv
reintroduc
antibodi
therapi
infecti
diseas
antibodi
molecul
exert
antimicrobi
activ
differ
mechan
includ
promot
phagocytosi
abdepend
cellular
cytotox
adcc
activ
complement
neutral
virus
toxin
modul
inflamm
affect
microbi
metabol
review
divers
function
make
possibl
tailor
ab
therapi
specif
diseas
depend
might
need
protect
exampl
antibodi
overcom
antiphagocyt
properti
encapsul
microb
streptococcu
pneumonia
cryptococcu
neoforman
promot
phagocytosi
fc
receptor
toxinneutr
properti
inhibit
deleteri
effect
toxigen
bacteria
bacillu
anthraci
versatil
associ
ab
therapi
amplifi
avail
differ
isotyp
differ
serum
halflif
effector
function
latter
partial
depend
fc
receptor
fcr
amplifi
reduc
inflammatori
respons
regard
efficaci
broadli
neutral
antibodi
hiv
depend
fcr
vaccineelicit
subclass
select
could
drive
optim
fcr
effector
function
nonneutr
antibodi
hiv
although
sever
type
ab
therapi
highli
success
noteworthi
date
avail
therapi
taken
full
advantag
either
ab
fcr
structur
function
divers
histor
ab
prepar
therapi
obtain
immun
anim
recov
individu
convalesc
sera
serum
therapi
pneumococcu
reli
larg
hors
immun
serum
anim
sera
effect
could
also
elicit
allerg
reaction
phenomenon
serum
sick
human
convalesc
sera
use
viral
diseas
specif
human
prepar
short
suppli
retrospect
carri
risk
inadvert
transmiss
blood
born
diseas
nevertheless
latter
half
th
centuri
immun
gamma
globulin
prepar
recommend
certain
clinic
set
prevent
therapi
diseas
caus
hepati
b
viru
cytomegaloviru
rabi
viru
tetanu
toxin
botulinum
toxin
among
other
sinc
monoclon
antibodi
avail
tool
exist
reduc
antigen
anim
antibodi
human
gener
fulli
human
ab
given
ab
natur
product
littl
inher
toxic
abil
reduc
elimin
antigen
mean
side
effect
associ
serum
therapi
significantli
diminish
perhap
greatest
differ
ab
convent
antimicrobi
therapi
exquisit
specif
immunoglobulin
molecul
target
unlik
antimicrobi
drug
function
indiscrimin
multipl
speci
antibodi
target
singl
speci
often
singl
serotyp
variant
within
speci
doubleedg
sword
develop
ab
therapi
great
specif
advantag
target
offend
microb
exampl
given
increas
evid
antibioticinduc
disrupt
microbiota
associ
deleteri
effect
treatment
bacteri
diseas
high
specif
abbas
therapi
offer
tremend
advantag
regard
limit
highli
specif
ab
fail
bind
highli
relat
variant
particularli
virus
two
strategi
overcom
problem
develop
ab
target
broadli
neutral
epitop
demonstr
hiv
dengu
influenza
virus
gener
ab
cocktail
compos
ab
multipl
serotyp
variant
done
rabi
viru
clostridium
difficil
toxin
similarli
although
sera
patient
recov
ebola
viru
diseas
exhibit
persist
neutral
activ
antibodi
differ
ebola
viru
strain
often
crossreact
strain
preantibiot
era
address
use
serotypespecif
sera
requir
isol
type
strain
institut
therapi
problem
especi
acut
mab
recogn
singl
epitop
limit
bypass
creat
cocktail
target
variou
subtyp
although
increas
cost
research
develop
mab
cocktail
also
design
neutral
differ
target
goal
achiev
higher
efficaci
synergi
noteworthi
experiment
mab
treatment
ebola
zmapp
consist
cocktail
three
mousehuman
chimer
ab
direct
viral
glycoprotein
reason
fulli
understood
ab
therapi
work
best
given
prophylact
mode
eg
infect
earli
cours
diseas
exampl
serum
therapi
treatment
pneumococc
pneumonia
effect
given
within
first
three
day
symptom
contrast
antimicrobi
agent
often
effect
establish
infect
diseas
one
propos
explan
limit
ab
work
best
neutral
infect
inoculum
cope
high
microbi
burden
establish
infect
altern
explan
ab
work
alter
inflammatori
respons
inflamm
establish
difficult
ab
exert
protect
function
viral
diseas
reduc
efficaci
ab
treatment
mode
could
reflect
molar
imbal
ab
molecul
increas
number
viral
particl
well
requir
cellmedi
immun
erad
establish
infect
whatev
explan
need
earli
administr
limit
therapi
sinc
mean
potenti
lack
efficaci
set
advanc
diseas
howev
contrast
antimicrobi
therapi
mediat
protect
drug
pharmacolog
avail
administr
ab
result
state
immedi
immun
combin
long
halflif
certain
immunolog
molecul
confer
longstand
state
reduc
suscept
contrast
convent
antimicrobi
therapi
ab
therapi
develop
extrem
quickli
sometim
midst
epidem
exampl
potenti
clinic
use
mab
coronaviru
respons
sever
acut
respiratori
syndrom
sar
rapidli
gener
month
use
epidem
contain
even
expedi
strategi
use
convalesc
serum
survivor
epidem
sourc
antibodi
treat
risk
concurr
diseas
past
convalesc
sera
use
treat
influenza
ebola
viru
diseas
today
convalesc
sera
survivor
ebola
viru
diseas
reportedli
use
treat
case
although
detail
sera
use
evid
efficaci
anecdot
nonetheless
note
least
three
establish
mechan
antibodi
function
could
benefit
patient
ebola
direct
neutral
ebola
viru
enhanc
ebola
viru
uptak
andor
kill
phagocyt
modul
ebolavirusinduc
inflammatori
respons
regard
latter
interest
immunomodul
propos
intervent
ebola
viru
anecdot
report
suggest
control
ebolavirusinduc
cytokin
storm
might
benefici
therapeut
despit
pioneer
use
ab
therapi
use
abbas
therapi
field
infecti
diseas
remain
work
progress
despit
enorm
technolog
progress
ab
engin
product
contrast
oncolog
rheumatolog
ab
therapi
common
two
licens
mab
infecti
diseas
one
prevent
respiratori
syncyti
viru
infect
therapi
anthrax
henc
abbas
therapi
sever
underdevelop
treatment
infecti
diseas
although
caus
complex
identifi
five
factor
case
interrel
yet
work
synergi
hinder
widespread
reintroduct
ab
therapi
field
cost
ab
therapi
gener
significantli
expens
small
molecul
must
produc
anim
cell
cultur
immunoglobulin
protein
requir
refriger
storag
turn
increas
cost
howev
one
consid
cost
antibioticassoci
coliti
damag
microbiota
resist
nontarget
organ
superinfect
result
nonspecif
therapi
cost
account
may
favor
ab
therapi
ii
specif
allud
specif
ab
therapi
mean
pathogen
specif
often
target
subgroup
organ
within
pathogen
speci
limit
bypass
creat
mab
cocktail
turn
increas
complex
product
cost
addit
cocktail
could
face
complic
regulatori
hurdl
therapi
compos
singl
activ
agent
despit
note
mab
cocktail
develop
ebola
viru
c
difficil
coliti
prevent
rabi
iii
market
size
profit
antimicrobi
spectrum
drug
combin
preval
diseas
caus
organ
efficaci
determin
market
size
law
pharmaceut
econom
favor
develop
broadspectrum
therapi
respons
widespread
resist
deleteri
effect
ab
therapi
host
microbiota
henc
exquisit
specif
mabbas
drug
de
facto
mean
smaller
market
size
turn
increas
cost
reduc
profit
make
reagent
suitabl
treat
specif
diseas
unattract
industri
iv
avail
exist
therapi
mani
infecti
diseas
current
avail
effect
therapi
mean
attempt
develop
ab
therapi
involv
establish
advantag
therapi
either
alon
combin
exist
therapi
greatli
complic
clinic
develop
market
field
therapi
avail
develop
ab
therapi
easier
provid
someth
new
howev
situat
may
chang
sinc
declin
efficaci
convent
antimicrobi
therapi
due
widespread
resist
could
creat
window
develop
abbas
therapi
v
underdevelop
diagnost
specif
ab
therapi
mean
effect
situat
precis
microbi
diagnosi
avail
bacteri
diseas
widespread
avail
broadspectrum
antimicrobi
drug
rel
littl
toxic
creat
cultur
empiric
translat
underdevelop
diagnost
consequ
microbi
cultur
remain
gold
standard
diagnosi
mani
infecti
diseas
decad
despit
avail
new
technolog
nucleic
acid
amplif
could
led
rapid
diagnosi
fortun
situat
chang
increas
recognit
problem
associ
broadspectrum
therapi
combin
declin
efficaci
drug
due
widespread
resist
lead
develop
use
rapid
diagnost
tool
could
support
use
abbas
therapi
ongo
ebola
epidem
provid
special
len
understand
promis
roadblock
develop
abbas
therapi
infecti
diseas
well
ethic
cultur
consider
pertain
conduct
clinic
trial
midst
epidem
underresourc
countri
preced
use
convalesc
sera
epidem
signal
promis
trial
sera
conduct
even
current
ebola
epidem
rage
note
stockpil
effect
ab
prepar
ebola
avail
earli
current
outbreak
administr
prepar
contact
might
provid
immedi
immun
possibl
result
earli
contain
epidem
prevent
thousand
death
fact
prepar
avail
earli
reflect
mani
factor
includ
cost
uncertainti
efficaci
lack
avail
market
erron
assess
base
prior
epidem
threat
would
small
local
suggest
also
made
therapi
remain
underdevelop
unattract
pharmaceut
industri
academ
investig
may
view
fit
current
drug
develop
model
cuttingedg
scienc
respect
howev
fact
abbas
therapi
ebola
develop
clinic
trial
sera
design
compassion
use
therapi
employ
midst
current
emerg
suggest
clinic
use
prepar
may
identifi
avail
shortli
near
horizon
like
abbas
therapi
continu
make
increment
advanc
repertoir
antiinfect
strategi
area
includ
infecti
diseas
caus
drugresist
organ
convent
therapi
lost
efficaci
diseas
avail
therapi
ebola
exampl
widespread
use
broadspectrum
therapi
associ
increas
c
difficil
coliti
creat
opportun
develop
toxinneutr
ab
therapi
far
horizon
optimist
abbas
therapi
wide
reintroduc
antiinfect
agent
given
inher
advantag
natur
product
low
toxic
high
specif
establish
efficaci
continu
technolog
advanc
form
effici
product
strategi
altern
product
sourc
express
plant
could
lower
cost
combin
new
therapeut
need
better
diagnost
make
use
attract
